AZD7762, MK-8776 (SCH 900776) and LY2606368 (prexasertib) are the most studied CHK1 inhibitors that have been investigated in combination with DNA-damaging agents in a variety of tumor entities. The gene discussed is CHEK1; the disease is neoplasm.